Newton, MA, United States of America

Solly Weiler

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 11.2

ph-index = 5

Forward Citations = 85(Granted Patents)


Company Filing History:


Years Active: 2012-2025

where 'Filed Patents' based on already Granted Patents

14 patents (USPTO):

Title: The Innovations of Solly Weiler: A Pioneer in Monoclonal Antibodies

Introduction

Solly Weiler, an esteemed inventor based in Newton, MA, has made significant contributions to the field of biotechnology, especially in the development of monoclonal antibodies. With a remarkable total of 13 patents to his name, Weiler continues to pave the way for innovative treatments targeting critical health issues.

Latest Patents

Among his latest inventions, Weiler is credited with the development of anti-GDF-15 antibodies. These monoclonal antibodies are engineered to bind and inhibit the activity of human GDF15, offering a novel approach to treat body weight loss, including cachexia, linked to the over-expression of this protein. Furthermore, he has also worked on anti-ErbB3 antibodies that inhibit the activation of the epidermal growth factor receptor-related member, ErbB3/HER3. This innovation holds promise for treating cell proliferative diseases and specific forms of cancer that are associated with the activation of ErbB3/HER3.

Career Highlights

Solly Weiler's career is marked by his role at Aveo Pharmaceuticals, Inc., where he has made remarkable strides in antibody development. His focus on creating targeted therapies has positioned him as a key player in the biotechnology sector, contributing to advanced treatments that can significantly improve patient outcomes.

Collaborations

Throughout his career, Weiler has collaborated with notable professionals, including William M Winston, Jr., and Jeno Gyuris. These partnerships have played a vital role in enhancing his research endeavors and expanding the scope of his innovations.

Conclusion

In summary, Solly Weiler stands out as a leading inventor in the biotechnology field, with a strong portfolio of patents reflecting his dedication to advancing medical science. His work on monoclonal antibodies not only exemplifies innovation but also represents a significant step forward in the treatment of various health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…